[HTML][HTML] Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner
S Yaqub, K Henjum, M Mahic, FL Jahnsen… - Cancer immunology …, 2008 - Springer
S Yaqub, K Henjum, M Mahic, FL Jahnsen, EM Aandahl, BA Bjørnbeth, K Taskén
Cancer immunology, immunotherapy, 2008•SpringerObjective Naturally occurring regulatory T (TR) cells suppress autoreactive T cells whereas
adaptive TR cells, induced in the periphery, play an important role in chronic viral diseases
and cancer. Several studies indicate that cyclooxygenase (COX) inhibitors prevent cancer
development of colon adenomas and delay disease progression in patients with colorectal
cancer (CRC). We have shown that adaptive TR cells express COX-2 and produce PGE 2
that suppress effector T cells in a manner that is reversed by COX-inhibitors. Methods and …
adaptive TR cells, induced in the periphery, play an important role in chronic viral diseases
and cancer. Several studies indicate that cyclooxygenase (COX) inhibitors prevent cancer
development of colon adenomas and delay disease progression in patients with colorectal
cancer (CRC). We have shown that adaptive TR cells express COX-2 and produce PGE 2
that suppress effector T cells in a manner that is reversed by COX-inhibitors. Methods and …
Objective
Naturally occurring regulatory T (TR) cells suppress autoreactive T cells whereas adaptive TR cells, induced in the periphery, play an important role in chronic viral diseases and cancer. Several studies indicate that cyclooxygenase (COX) inhibitors prevent cancer development of colon adenomas and delay disease progression in patients with colorectal cancer (CRC). We have shown that adaptive TR cells express COX-2 and produce PGE2 that suppress effector T cells in a manner that is reversed by COX-inhibitors.
Methods and results
Here we demonstrate that CRC patients have elevated levels of PGE2 in peripheral blood, and CRC tissue samples and draining lymph nodes display increased numbers of FOXP3+ TR cells. Depletion of TR cells from PBMC enhanced anti-tumor T-cell responses to peptides from carcinoembryonic antigen. Furthermore, the COX inhibitor indomethacin and the PKA type I antagonist Rp-8-Br-cAMPS significantly improved the anti-tumor immune activity.
Conclusion
We suggest that adaptive TR cells contribute to an immunosuppressive microenvironment in CRC and inhibit effector T cells by a COX-2–PGE2-dependent mechanism and thereby facilitate tumor growth. Therapeutic strategies targeting TR cells and the PGE2–cAMP pathway may be interesting to pursue to enhance anti-tumor immune activity in CRC patients.
Springer